Full-Time
Post Market Surveillance Specialist
Posted on 6/16/2025
ENOVIS
1,001-5,000 employees
Global medical technology company; orthopedic solutions
No salary listed
Friuli-Venezia Giulia, Italy
In Person
 Legal & Compliance (2) |
|---|
| , |
- Typically requires a degree and a minimum of 2 years of experience.
- Performs the coordination and preparation of document packages for regulatory submissions for new and mature products to ensure alignment and compliance with local and regional registration requirements as well as with company policies from all areas of company as well as internal audits and inspections.
- Compiles all materials required in submissions, license renewal and annual registrations.
- Recommends changes for labeling, manufacturing and clinical protocol for regulatory compliance.
- Monitors and improves tracking/control systems.
- Keeps abreast of regulatory procedures and changes.
- May direct interaction with regulatory agencies on defined matters.
- Recommends strategies for earliest possible approvals of clinical trials applications.
- General application of concepts and principals to resolve a variety of issues.
- Works on problems of a moderate scope where analysis of situation or data requires a review of a variety of factors.
- Normally receives general instructions on routine work and detailed instructions on new projects or assignments.
Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
2022
Simplify's Take
What believers are saying
- LimaCorporate expands Enovis's reconstructive implant scale in Europe and the United States.
- ARVIS and extremities launches are driving double-digit shoulder growth.
- Spinamic may improve scoliosis compliance through rigid correction and breathable comfort.
What critics are saying
- Goodwill impairment signals acquisition returns have not met capital expectations.
- ARVIS adoption remains early, with limited procedure history outside the United States.
- Debt maturity to 2030 still leaves refinancing pressure if growth disappoints again.
What makes ENOVIS unique
- Enovis combines orthopedics, rehabilitation, and surgical productivity across two segments.
- Its DonJoy, Aircast, Exos, and Chattanooga brands have broad clinician recognition.
- EGX emphasizes continuous operational improvement across more than 30 global facilities.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at ENOVIS who can refer or advise you
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Legal Services
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 32%Enovis Corporation has reported strong organic revenue growth driven by new product launches, including the Nebula Stem and OrthoDrive Impactor, which have seen rapid market uptake. The medical technology company's devices are gaining traction with surgeons and hospitals. However, Enovis recorded a significant goodwill impairment charge in its fourth quarter and full-year results, affecting its balance sheet. The impairment raises questions about returns from previous acquisitions and future capital allocation strategy. Trading at $25.47, Enovis shares are approximately 44% below the analyst price target of $45.18. The company currently shows a loss of $1.18 billion and trades at a forward price-to-earnings ratio of 25.73 times. Investors are advised to monitor how product adoption and procedure volumes affect future cash flow.
Enovis Corporation shares jumped 12.6% in morning trading after the medical technology company reported mixed fourth-quarter results but issued a strong earnings forecast for 2026. Whilst quarterly revenue of approximately $576 million missed expectations, adjusted earnings per share of $0.95 beat analyst estimates. The stock surge was driven by Enovis's 2026 earnings guidance of $3.52 to $3.73 per share, with the midpoint significantly exceeding analyst projections. This positive profit outlook overshadowed the revenue shortfall. Enovis shares have experienced high volatility, with 26 moves exceeding 5% over the past year. The stock is down 6.6% year-to-date and trading 38.1% below its 52-week high of $40 from March 2025.
Enovis Corporation reported a fourth-quarter loss of $520.6 million, or $9.10 per share. The Wilmington, Delaware-based manufacturing and engineering company posted adjusted earnings of 95 cents per share, excluding asset impairment and non-recurring costs. Revenue for the quarter reached $575.8 million. For the full year, Enovis reported a loss of $1.18 billion, or $20.75 per share, on revenue of $2.25 billion.
Enovis Corporation has received positive analyst coverage, with BTIG initiating a Buy rating and $41 price target on 6 January. The orthopedic care company is expected to see accelerated growth in 2026 driven by new product launches across extremities, hips and knees. BTIG highlighted the company's consistent mid-to-high single-digit organic revenue growth in its Reconstruction and Prevention & Recovery segments. The higher-growth Reconstruction business is expected to drive margins whilst the mature Prevention & Recovery segment delivers steady cash flow. UBS maintained its Buy rating but lowered its price target to $50 from $57, projecting sales of $2.26 billion in 2025, $2.37 billion in 2026 and $2.52 billion in 2027.
Enovis Corp has entered Amendment No. 3 to its credit agreement on 8 December, extending the loan maturity date to 8 December 2030. The amended agreement provides a revolving credit facility of up to $1.1 billion and a term loan facility of $700 million. The company used term loan proceeds to repay $335 million from its revolving facility. The amendment restructures Enovis's debt arrangements, providing the medical technology company with extended financing flexibility through the end of the decade.